bignewsnetwork.com
Cure8 news brief
Mubadala Bio launches two immunology therapies - Big News Network.com
Medications
Adalimumab
Ustekinumab
Anti-TNF
IL-12/23 inhibitor
Patient Education
Patients On Biologics
Clinicians
Why This Matters
Launches of adalimumab and ustekinumab could expand local access to two widely used biologic treatments for Crohn’s disease and ulcerative colitis. Wider availability may affect treatment options and logistics for people with IBD in regions served by the company.
Who Should Pay Attention
Patients with Crohn's disease or ulcerative colitis, clinicians who prescribe biologics, caregivers in the UAE/region, and patients interested in biologic access.
Study Snapshot
Story typeMainstream News
Evidence typePatient Education
Source depthFull source text
What To Know
Mubadala Bio says it has launched adalimumab (an anti-TNF monoclonal antibody) and ustekinumab (an antibody targeting IL-12/23 pathways) as part of its biologics portfolio in the UAE. The piece emphasizes access and the company’s strategy to localize advanced therapies rather than presenting new clinical data.
If you have IBD, this may mean another supplier or route to obtain these established biologic options locally, but treatment decisions, dosing, and monitoring remain clinical matters for your healthcare provider.
Keep In Mind
This is a company announcement about product launches and general indications; it does not provide clinical trial data, pricing, formulary or availability specifics. Prescriptions and treatment decisions require a licensed healthcare professional.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationbignewsnetwork.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 7, 2026, 7:57 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
Impact of Smoking on the Effectiveness of Advanced Therapies in Inflammatory Bowel Disease: Active Smoking Is Associated with Reduced Effectiveness of Anti-TNF Treatment
The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...
Patterns and factors associated with dose escalation during maintenance treatment for inflammatory bowel disease: a population-based cohort study.
Dose increases are common during IBD maintenance and vary a lot by drug and patient profile. Knowing which treatments and patient factors are linked to escalation can help patients and clinicians plan monitoring and...